30-09-2021 | EASD 2021 | Conference coverage | News
AF, PAD, diabetes prevention data reported from DAPA-CKD
The latest DAPA-CKD data show the large absolute benefits of dapagliflozin treatment in people with peripheral artery disease or atrial fibrillation, and that the medication may reduce the risk for type 2 diabetes in people with initial prediabetes.
29-08-2021 | ESC 2021 | Conference coverage | News
Empagliflozin has broad beneficial effect on HFpEF outcomes
Empagliflozin treatment produces significant reductions in the risk for a broad range of inpatient and outpatient heart failure outcomes in people with a preserved ejection fraction, shows further analysis of EMPEROR-Preserved.
27-08-2021 | ESC 2021 | Conference coverage | News
EMPEROR-Preserved: A win for empagliflozin in HFpEF
Empagliflozin has become the first medication to demonstrate a clear protective effect in people with heart failure and preserved ejection fraction, report the EMPEROR-Preserved investigators.
Pregnant patient measuring blood sugar/© Людмила Ильина / stock.adobe.com, Hear pills/© David G / Fotolia